Dupilumab is associate with significantly reduce severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study present at the American Thoracic Society 2019 International Conference, held from May 17 to 22 in Dallas.

Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some people, asthma is a minor nuisance. For others, it can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack.

Combination of genetic

Asthma is thought to be cause by a combination of genetic and environmental factors. Environmental factors include exposure to air pollution and allergens. Other potential triggers include medications such as aspirin and beta blockers. Diagnosis is usually base on the pattern of symptoms; so response to therapy over time, and spirometry.

Asthma is classify according to the frequency of symptoms; so force expiratory volume in one second (FEV1), and peak expiratory flow rate. It may also be classify as atopic or non atopic; where atopy refers to a predisposition toward developing a type 1 hypersensitivity reaction. Asthma can’t be cured; but its symptoms can be controlled. Because asthma often changes over time; it’s important that you work with your doctor to track your signs and symptoms and adjust treatment as needed.

Nicola Alexander Hanania, M.D., from the Baylor College of Medicine in Houston; also colleagues examine the efficacy of dupilumab in patients; so with late onset asthma and with baseline post bronchodilator force expiratory volume in one second/force vital capacity (FEV1/FVC) ratio <0.7 (indicating fixed airway obstruction) or ≥0.7 in a post hoc analysis of data from the phase 3 LIBERTY ASTHMA QUEST study.

Onset asthma patients

The researchers find that compare with placebo; so dupilumab 200 mg and 300 mg every two weeks significantly reduce the annualize; so rate of severe exacerbations in patients with late onset asthma; also fix airway obstruction (−68.8 and −75.7 %, respectively) and in patients without fix airway obstruction (−55.1 and −50.7%, respectively).

Pre and postbronchodilator FEV1 and FEV1/FVC ratio improve in dupilumab treat patients with late-onset asthma and fix airway obstruction at week 12; similar improvements were see at week 52. More modest improvements were see for pre bronchodilator FEV1 at weeks 12 and 52 in late onset asthma patients without fix airway obstruction.

“Lung function improvements were observe at Weeks 12 and 52 in patients with late onset asthma and fix airway obstruction, who typically experience worse asthma outcomes than do those without fix airway obstruction,” the authors write. Several authors disclose financial ties to Sanofi and Regeneron Pharmaceuticals, the manufacturers of dupilumab.